Skandinaviska Enskilda Banken AB publ Takes $425,000 Position in Exelixis, Inc. (NASDAQ:EXEL)

Skandinaviska Enskilda Banken AB publ purchased a new position in Exelixis, Inc. (NASDAQ:EXEL) in the 4th quarter, HoldingsChannel.com reports. The fund purchased 12,600 shares of the biotechnology company’s stock, valued at approximately $425,000.

A number of other large investors also recently added to or reduced their stakes in EXEL. USA Financial Formulas purchased a new stake in shares of Exelixis during the fourth quarter worth about $32,000. Principal Securities Inc. increased its stake in Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock worth $32,000 after buying an additional 373 shares in the last quarter. Kestra Investment Management LLC acquired a new position in shares of Exelixis during the fourth quarter valued at approximately $39,000. Brooklyn Investment Group purchased a new position in shares of Exelixis in the third quarter valued at approximately $42,000. Finally, UMB Bank n.a. boosted its stake in shares of Exelixis by 68.4% in the fourth quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 553 shares during the last quarter. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts recently commented on EXEL shares. Oppenheimer downgraded Exelixis from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $41.00 to $33.00 in a research note on Friday, January 24th. Stifel Nicolaus increased their target price on shares of Exelixis from $30.00 to $36.00 and gave the company a “hold” rating in a research report on Wednesday, February 12th. StockNews.com upgraded shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, February 19th. UBS Group increased their price objective on shares of Exelixis from $30.00 to $34.00 and gave the company a “neutral” rating in a report on Tuesday, January 28th. Finally, Brookline Capital Management started coverage on Exelixis in a report on Monday, December 23rd. They set a “buy” rating on the stock. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Exelixis presently has an average rating of “Moderate Buy” and an average target price of $37.59.

Insiders Place Their Bets

In related news, EVP Patrick J. Haley sold 10,000 shares of the business’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $38.80, for a total value of $388,000.00. Following the sale, the executive vice president now owns 341,028 shares in the company, valued at approximately $13,231,886.40. The trade was a 2.85 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jack L. Wyszomierski sold 8,768 shares of the firm’s stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $37.80, for a total value of $331,430.40. Following the transaction, the director now owns 356,605 shares of the company’s stock, valued at $13,479,669. This trade represents a 2.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 140,343 shares of company stock worth $5,177,234 over the last ninety days. Corporate insiders own 2.85% of the company’s stock.

Exelixis Trading Up 1.0 %

Shares of EXEL opened at $37.02 on Tuesday. The company’s 50-day moving average price is $35.44 and its 200 day moving average price is $32.60. Exelixis, Inc. has a 12-month low of $20.14 and a 12-month high of $40.02. The firm has a market cap of $10.36 billion, a P/E ratio of 20.92, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. Equities research analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.